Articles tagged "Immunosuppression"

2015 American Transplant Congress
Dual PI3K-mTOR Inhibition on Human T Cell Activation, Proliferation, and Differentiation: The First Step in the Development of New Immunosuppressants
V. Vilchez,¹ A. Castellanos,¹ D. Butterfield,³ M. Mitov,³ C. Hoopes,¹ F. Marti,² R. Gedaly.¹
¹Department of Surgery - Transplant Section, University of Kentucky, Lexington, KY; ²Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY; ³Free Radical Biology in Cancer Shared Resource Facility, University of Kentucky, Lexington, KY.
Background: Regulatory T lymphocytes (Tregs) contribute to transplant tolerance. We have demonstrated that the inhibition of PI3K-mTOR pathway has a major role in the differentiation…
2015 American Transplant Congress
Induction of iNOS Expressed Macrophages from Mouse iPS cells That Contribute to Prolong Same iPS Cells-Derived Graft Survival in Allogeneic Recipients
H. Sasaki,¹ H. Wada,² K. Morita,¹ K.-I. Seino,² N. Shinohara.¹
¹Genitourinary Surgery, Hokkaido University, Sapporo, Japan; ²Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
BACKGROUND: Induced pluripotent stem cells (iPSCs)-technology provides new opportunities in regenerative medicine to generate grafts from donors for transplantation. However, particularly when allogeneic iPSCs are…
2015 American Transplant Congress
Variants Associated With Tacrolimus Troughs in European American Kidney Transplant Recipients: A Genome Wide Association Study
P. Jacobson,¹ M. Miller,² D. Schladt,³ A. Israni,³ K. Sanghavi,¹ C. Dorr,³ R. Remmel,¹ W. Guan,⁴ A. Matas,⁵ W. Oetting.¹
¹College of Pharmacy, University of MN, Minneapolis, MN; ²Department of Psychology, University of MN, Minneapolis, MN; ³Department of Nephrology and Chronic Disease Research Group, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minneapolis, MN; ⁴Department of Biostatistics, University of MN, Minneapolis, MN; ⁵Department of Surgery, University of MN, Minneapolis, MN.
Tacrolimus (tac) is dependent on CYP3A4/5 for metabolism. Variability in the metabolism is influenced by CYP3A5*3 alleles. This variant and clinical factors explain around 50%…
2015 American Transplant Congress
Does Infection Impact On Tacrolimus Blood Levels in Kidney Transplant Recipients?
N. Kanaan,¹ C. Percy,¹ Z. Hassoun,² M. Mourad,³ C. Beguin,⁴ M. De Meyer,³ E. Goffin.¹
¹Nephrology, Cliniques Universitaires Saint Luc, Brussels, Belgium; ²Gastroenterology, Cliniques Universitaires Saint Luc, Brussels, Belgium; ³Abdominal Surgery and Transplantation, Cliniques Universitaires Saint Luc, Brussels, Belgium; ⁴Medical Information and Statistics, Cliniques Universitaires Saint Luc, Brussels, Belgium.
Background Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy in kidney transplant recipients. It is metabolized by members of the cytochrome p450 (CYP) 3A subfamily…
2015 American Transplant Congress
Development and Validation of a Genotype Guided Tacrolimus Dosing Equation for African American (AA) Kidney Transplant Recipients
K. Sanghavi,¹ R. Brundage,¹ M. Miller,² D. Schaldt,³ A. Israni,³ W. Guan,⁴ W. Oetting,¹ R. Mannon,⁵ R. Remmel,¹ A. Matas,⁶ P. Jacobson.¹
¹College of Pharmacy, University of MN, Minneapolis, MN; ²Dept of Psychology, University of MN, Minneapolis, MN; ³Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minneapolis, MN; ⁴Dept of Biostatistics, University of MN, Minneapolis, MN; ⁵Dept of Nephrology, University of AL, Birmingham, AL; ⁶Dept of Surgery, University of MN, Minneapolis, MN.
Tacrolimus (tac) has a strong exposure-response relationship with high inter-individual variability in troughs and dose. Tac dose requirements for AA patients are higher than Caucasians,…
2015 American Transplant Congress
Calcineurin-Inhibitor Conversion to mTOR Inhibitor in Renal Transplant Recipients Leads to Worse Long Term Clinical Outcomes
A. Alvarado,¹ A. Shetty,¹ O. Traitanon,¹ J. Leventhal,¹ V. Mas,² D. Chhabra,³ J. Matthews,¹ L. Gallon.¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²University of Virgina, Charlottesville, Va; ³Advocate Christ Medical Center, Chicago, IL.
We previously reported the short-term feasibility of Calcineurin-Inhibitor (CNI) elimination in kidney transplant recipients. We now report the long-term clinical impact on renal allograft function…
2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
W. Arns,¹ K. Budde,¹ C. Sommerer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ P. Reinke,¹ I. Hauser,¹ R. Stahl,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ V. Kliem.¹
¹Herakles Study Group, Germany; ²Novartis, Pharma, Germany; ³Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…
2015 American Transplant Congress
Deceased Donor Kidney Transplantation Without Calcineurin Inhibitors or Steroids
A. Kirk,^1,2 A. Guasch,¹ S. Mead,¹ A. Ghali,¹ A. Mehta,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson.¹
¹Transplant Center, Emory University, Atlanta, GA; ²Surgery, Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…
2015 American Transplant Congress
Defining the Role of CD57+CD4 T Cells in Belatacept-Resistant Rejection
J. Espinosa,^1,2 L. Stempora,^1,2 R. Townsend,³ A. Kirk.^1,2
¹Duke University, Durham, NC; ²Emory University, Atlanta, GA; ³Bristol-Myers Squibb, Princeton, NJ.
Purpose: We have shown that CD57+PD1- CD4 T cells are present in higher numbers in the peripheral blood and allograft biopsies of patients who experienced…
2015 American Transplant Congress
ASKP1240 in De Novo Kidney Transplant Recipients
R. Harland,¹ G. Klintmalm,² H. Yang,³ S. Jensik,⁴ T. Shah,⁵ P. West-Thielke,⁶ F. Shihab,⁷ W. Zhang,⁸ V. Santos,⁸ R. Tainaka,⁸ X. Wang,⁸ R. First,⁸ J. Holman.⁸
¹East Carolina University, Greenville, NC; ²Baylor University Medical Center, Dallas, TX; ³Pinnacle Health System, Harrisburg, PA; ⁴Rush University, Chicago, IL; ⁵Transplant Research Institute, Los Angeles, CA; ⁶University of Illinois Chicago, Chicago, IL; ⁷University of Utah Health Science Center, Salt Lake City, UT; ⁸Astellas Pharma Global Development, Northbrook, IL.
Primary objective was to evaluate the efficacy and safety of ASKP1240, antagonistic anti-CD40 antibody, in either a CNI free regimen or a CNI minimization regimen…